This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van den Abbeele, A. D. Search for Related Content PubMed PubMed Citation Articles by Van den Abbeele, A. D.

The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Key Words. Positron emission tomography • Computed tomography • Fluorodeoxyglucose • Gastrointestinal stromal tumor • Imatinib mesylate

Correspondence: Annick D. Van den Abbeele, M.D., Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Telephone: 617-632-2595; Fax: 617-582-8574; e-mail: abbeele{at}dfci.harvard.edu

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Traditional anatomic tumor response criteria are based on uni- or bidimensional changes in tumor size, and do not take into account changes in tumor metabolism, tumor density, or decrease in the number of intratumoral vessels. These changes are, however, all indicative of response to imatinib therapy in patients with gastrointestinal stromal tumor (GIST). In these patients, metabolic responses seen on positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (¹⁸FDG) have been shown to be closely related to clinical benefit. Furthermore, these metabolic changes precede by weeks or months significant decrease in tumor size on computed tomography (CT). Conversely, lack of metabolic response on FDG-PET indicates primary resistance to the drug and may help identify patients who would benefit from another therapy, while re-emergence of metabolic activity within tumor sites following a period of therapeutic response indicates secondary resistance to the drug. Newly proposed CT criteria using either no growth in tumor size or a combination of tumor density and size criteria have shown a close correlation with the predictive value results of FDG-PET. Thus, the integration of FDG-PET and CT, as in the combined hybrid PET/CT scanners now available, will not only optimize the evaluation of patients with GIST treated with molecularly targeted drugs, but may ultimately help shorten clinical trials, and accelerate drug development in this disease and other cancers as well.

This article has been cited by other articles:

				C. C. Jaffe Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design Oncologist, April 1, 2008; 13(suppl_2): 14 - 18. [Abstract] [Full Text] [PDF]

				S. M. Schuetze, L. H. Baker, R. S. Benjamin, and R. Canetta Selection of Response Criteria for Clinical Trials of Sarcoma Treatment Oncologist, April 1, 2008; 13(suppl_2): 32 - 40. [Abstract] [Full Text] [PDF]